Skip to main content

Cerevel Therapeutics Holdings, Inc. (CERE)

NASDAQ: CERE · IEX Real-Time Price · USD
37.45
-0.12 (-0.32%)
After-hours:Sep 17, 2021 6:18 PM EDT
37.57
1.09 (2.99%)
At close: Sep 17, 4:00 PM
Market Cap5.44B
Revenue (ttm)n/a
Net Income (ttm)-199.08M
Shares Out144.87M
EPS (ttm)-1.62
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,631,412
Open36.75
Previous Close36.48
Day's Range35.63 - 37.99
52-Week Range9.00 - 37.99
Betan/a
Analystsn/a
Price Target33.00 (-12.2%)
Est. Earnings DateNov 11, 2021

About CERE

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in Phase Ib clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as Phase I proof-of-principle trial for acute anxiety. The company's products also comprise Tavapadon, a se...

IndustryBiotechnology
Founded2018
Employees148
Stock ExchangeNASDAQ
Ticker SymbolCERE
Full Company Profile

Financial Performance

Financial Statements

News

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fid...

New York, New York--(Newsfile Corp. - September 15, 2021) - Levi & Korsinsky announces it has commenced an investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) concerning possible breache...

3 days ago - Newsfile Corp

Cerevel Therapeutics to Host Virtual R&D Event on October 7

Event will focus on CVL-871, a D1/D5 partial agonist in development for dementia-related apathy, and will include an update on CVL-231, an M4 positive allosteric modulator for the treatment of schizophr...

1 week ago - GlobeNewsWire

3 Biotech Stocks That Soared to New Heights Last Week

Find out what these industry favorites are doing to impress investors.

Other symbols:ADGIBCYC
2 weeks ago - The Motley Fool

3 Stocks Insiders Are Buying

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.

Other symbols:DNUTSXT
2 weeks ago - Benzinga

Should Investors Follow Private Equity into Life Sciences?

Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new fun...

Other symbols:BBCBNTXCNCRIEIHPFE
4 weeks ago - GuruFocus

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fid...

New York, New York--(Newsfile Corp. - August 12, 2021) - Levi & Korsinsky announces it has commenced an investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) concerning possible breaches o...

1 month ago - Newsfile Corp

Cerevel Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates

Announced positive topline results for CVL-231 in Phase 1b trial in schizophrenia

1 month ago - GlobeNewsWire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fi...

New York, New York--(Newsfile Corp. - August 2, 2021) - Levi & Korsinsky announces it has commenced an investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) concerning possible breaches of...

1 month ago - Newsfile Corp

Cerevel Therapeutics Announces Redemption of Public Warrants

CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE; CEREW) (the “Company”), a company dedicated to unraveling the mysteries of the brain to treat neuroscience disease...

1 month ago - GlobeNewsWire

Cerevel Therapeutics to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021

CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it w...

1 month ago - GlobeNewsWire

Why Cerevel Therapeutics Is Up More Than 29% in the First Half of 2021

A positive early stage trial for a schizophrenia drug has pushed this biotech's stock this year.

1 month ago - The Motley Fool

New Analyst Coverage Puts Spotlight on These 4 Stocks

Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like HIBB, ITGR, CERE and ATEN.

Other symbols:ATENHIBBITGR
2 months ago - Zacks Investment Research

Here's What's Pushing Cerevel Therapeutics Stock Lower Today

Investors aren't thrilled about how this biotech intends to pay operating expenses that are about to balloon.

2 months ago - The Motley Fool

Cerevel Therapeutics Announces Pricing of $350 Million Public Offering of Common Stock

CAMBRIDGE, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the ...

2 months ago - GlobeNewsWire

Cerevel (CERE) Novel Schizophrenia Drug Succeeds in Phase I

Cerevel Therapeutics (CERE) surges as schizophrenia candidate, CVL-231, demonstrates clinically meaningful and statistically significant improvement in PANSS Total score at 6 weeks in phase Ia study.

2 months ago - Zacks Investment Research

Cerevel Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that...

2 months ago - GlobeNewsWire

CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing

Cerevel Therapeutics is taking on schizophrenia with its newest drug treatment. After posting positive trial results, CERE stock is up big.

2 months ago - InvestorPlace

These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday

You might not have heard of them, but one went up big while the other served up a massive disappointment.

Other symbols:SNSE
2 months ago - The Motley Fool

Here's Why Cerevel Therapeutics Stock Is Shooting Through the Roof Today

Positive topline results from the company's schizophrenia candidate were better than expected.

Other symbols:PFE
2 months ago - The Motley Fool

Cerevel Therapeutics Announces Positive Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schiz...

Both doses of CVL-231 demonstrated a clinically meaningful and statistically significant improvement in PANSS Total score at 6 weeks and were overall well-tolerated compared with placebo

2 months ago - GlobeNewsWire

Cerevel Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to CVL-871 for the Treatment of Dementi...

CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that the U...

3 months ago - GlobeNewsWire

Cerevel Therapeutics to Present at Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that it wil...

3 months ago - GlobeNewsWire

Cerevel Therapeutics Reports First Quarter 2021 Financial Results and Business Updates

Announced strategic $125 million non-dilutive financing for tavapadon

4 months ago - GlobeNewsWire

Cerevel Therapeutics to Report First Quarter 2021 Financial Results on Monday, May 17, 2021

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it...

4 months ago - GlobeNewsWire

Cerevel Therapeutics Appoints Abraham N. Ceesay as President

CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of...

4 months ago - GlobeNewsWire